Table 1. Input parameters.
Variable | Estimate | Source, year publication (reference) | |
---|---|---|---|
Symptom classes | Probabilities (%) | ||
Non-overlapping | Overlapping | ||
Chronic fatigue | 42.99 | 72.1 | Health Infobase, 2022 ((13)) |
Psychiatric conditions | 14.43 | 24.2 | |
Cognitive conditions | 19.62 | 32.9 | |
Respiratory disease | 22.96 | 38.5 | |
Likelihood of becoming a PCC case (by vaccination status) | |||
Unvaccinated | 41.8 | N/A | Azzolini et al., 2022 ((14)) |
1st dose | 30.0 | ||
2nd dose | 17.4 | ||
3rd dose | 16.0 | ||
Health related quality of life decrements | |||
Chronic fatigue | 0.36 | Versteegh et al., 2016 ((15)) | |
Psychiatric conditions | 0.21 | Steensma et al., 2016 ((16)) | |
Cognitive conditions | 0.12 | Song et al., 2022 ((17)) | |
Respiratory disease | 0.37 | Van Wilder et al., 2019 ((18)) | |
Costs (Canadian dollars) | |||
Chronic fatigue | 12,753 | Jason et al., 2008 ((19)) | |
Psychiatric conditions | 4,123 | Chiu et al., 2017 ((20)) | |
Cognitive conditions | 9,939 | Zhu et al., 2013 ((21)) | |
Respiratory disease | 10,641 | Bonafede et al., 2011 ((22)) | |
Other variables | |||
Number of patients with at least one PCC symptom | Low: 0.74 million Medium: 2.02 million High: 2.88 million |
Health Infobase, 2023 ((23)) Health Infobase, 2023 ((24)) Statistics Canada, 2023 ((25)) |
Abbreviations: N/A, not applicable; PCC, post-COVID-19 condition (COVID-19, coronavirus disease 2019)